<DOC>
	<DOCNO>NCT00003357</DOCNO>
	<brief_summary>RATIONALE : Vaccines make GM2-KLH give QS21 may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness GM2-KLH vaccine plus QS21 treat patient breast cancer evidence disease .</brief_summary>
	<brief_title>Vaccine Therapy Plus QS21 Treating Women With Breast Cancer Who Have No Evidence Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether immunization GM2-KLH vaccine plus immunological adjuvant QS21 induce antibody response GM2 cell express GM2 disease free patient high risk recurrence breast cancer . OUTLINE : GM2-KLH vaccine plus QS21 administer subcutaneously sit upper arm upper leg weekly interval 4 week . Two additional vaccine administer week 12 24 . Patients follow every 3 month sixth vaccination . PROJECTED ACCRUAL : A total 9 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Eligible patient must evidence disease addition 1 follow feature : Stage I , II , III breast cancer receive adjuvant chemotherapy remain clinically free identifiable disease , rise CA15.3 ( BR2729 ) CEA level Stage III breast cancer complete adjuvant therapy 24 month ago Recurrence ipsilateral axilla follow lumpectomy/axillary dissection modify radical mastectomy Recurrence ipsilateral breast follow lumpectomy/axillary dissection Stage II breast cancer least 4 positive axillary lymph node 24 month follow completion adjuvant therapy Patients isolated elevation CEA level must colonoscopy rule colon carcinoma A colonoscopy within past 5 year acceptable strong family history colon carcinoma , colonic polyp , inflammatory bowel disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Premenopausal postmenopausal Performance status : Karnofsky 90100 % Life expectancy : Not specify Hematopoietic : Lymphocyte count least 500/mm3 WBC count least 3,000/mm3 Hepatic : Aspartate aminotransferase great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV cardiac disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent active cancer except basal cell squamous cell carcinoma skin No history seafood allergy No known history immunodeficiency autoimmune disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : No concurrent steroids Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage III breast cancer</keyword>
</DOC>